Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP481419.RAxmEikEaljAhXk83ZCyclQdrOxYVAtvye_pH7VsqJTVk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP481419.RAxmEikEaljAhXk83ZCyclQdrOxYVAtvye_pH7VsqJTVk130_assertion type Assertion NP481419.RAxmEikEaljAhXk83ZCyclQdrOxYVAtvye_pH7VsqJTVk130_head.
- NP481419.RAxmEikEaljAhXk83ZCyclQdrOxYVAtvye_pH7VsqJTVk130_assertion description "[Furthermore, in patient samples with HNC (n = 51) analyzed by quantitative MSP, NEFL promoter hypermethylation was associated with resistance to cisplatin-based chemotherapy [relative risk (RR), 3.045; 95% confidence interval (CI), 1.459-6.355; P = 0.007] and predicted diminished overall and disease-free survival for patients treated with cisplatin-based chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP481419.RAxmEikEaljAhXk83ZCyclQdrOxYVAtvye_pH7VsqJTVk130_provenance.
- NP481419.RAxmEikEaljAhXk83ZCyclQdrOxYVAtvye_pH7VsqJTVk130_assertion evidence source_evidence_literature NP481419.RAxmEikEaljAhXk83ZCyclQdrOxYVAtvye_pH7VsqJTVk130_provenance.
- NP481419.RAxmEikEaljAhXk83ZCyclQdrOxYVAtvye_pH7VsqJTVk130_assertion SIO_000772 22246235 NP481419.RAxmEikEaljAhXk83ZCyclQdrOxYVAtvye_pH7VsqJTVk130_provenance.
- NP481419.RAxmEikEaljAhXk83ZCyclQdrOxYVAtvye_pH7VsqJTVk130_assertion wasDerivedFrom befree-20140225 NP481419.RAxmEikEaljAhXk83ZCyclQdrOxYVAtvye_pH7VsqJTVk130_provenance.
- NP481419.RAxmEikEaljAhXk83ZCyclQdrOxYVAtvye_pH7VsqJTVk130_assertion wasGeneratedBy ECO_0000203 NP481419.RAxmEikEaljAhXk83ZCyclQdrOxYVAtvye_pH7VsqJTVk130_provenance.